Table 1.
Five- and 10-year estimates of PFS, LRF, DM, and OS
| Endpoint | Primary sites | RT + cisplatin | RT + cisplatin + cetuximab | ||
|---|---|---|---|---|---|
| 5-y estimate (95% CI) | 10-y estimate (95% CI) | 5-y estimate (95% CI) | 10-y estimate (95% CI) | ||
| PFS | All | 56.0% (51.3–60.7) | 43.6% (38.8–48.4) | 52.9% (48.2–57.7) | 40.2% (35.4–45.0) |
| p16-positive OPC | 73.7% (65.5–81.9) | 62.8% (53.5–72.2) | 63.9% (55.4–72.4) | 53.1% (43.9–62.3) | |
| Non-OPC or p16-negative OPC | 42.7% (35.3–50.0) | 27.0% (20.1–33.9) | 43.7% (36.1–51.3) | 29.4% (22.1–36.7) | |
| LRF | All | 22.7% (18.9–26.7) | 28.5% (24.2–32.9) | 28.8% (24.5–33.1) | 34.8% (30.3–39.5) |
| p16-positive OPC | 10.8% (5.9–17.5) | 14.1% (8.2–21.4) | 25.4% (18.0–33.4) | 27.6% (19.8–35.9) | |
| Non-OPC or p16-negative OPC | 32.1% (25.3–39.1) | 40.0% (32.5–47.3) | 31.8% (24.8–39.0) | 38.3% (30.6–45.9) | |
| DM | All | 13.9% (10.9–17.4) | 15.0% (11.8–18.6) | 10.8% (8.1–14.0) | 11.8% (9.0–15.1) |
| p16-positive OPC | 10.0% (5.3–16.5) | 10.0% (5.3–16.5) | 7.4% (3.6–13.0) | 8.4% (4.3–14.3) | |
| Non-OPC or p16-negative OPC | 17.7% (12.4–23.7) | 19.7% (14.1–26.0) | 12.9% (8.3–18.5) | 12.9% (8.3–18.5) | |
| OS | All | 65.0% (60.5–69.5) | 49.9% (45.0–54.8) | 65.9% (61.4–70.5) | 50.0% (45.1–54.9) |
| p16-positive OPC | 84.5% (77.7–91.3) | 69.6% (60.5–78.6) | 78.7% (71.4–85.9) | 66.4% (57.6–75.1) | |
| Non-OPC or p16-negative OPC | 50.0% (42.4–57.5) | 33.1% (25.8–40.4) | 53.3% (45.6–61.1) | 35.7% (28.0–43.4) | |
Abbreviations: CI = confidence interval; DM = distant metastasis; LRF = locoregional failure; OPC = oropharyngeal cancer; OS = overall survival; PFS = progression-free survival; RT = radiation therapy.